AUTHOR=Hu Ran , Liu Yuanbao , Zhang Lei , Kang Guodong , Xu Borong , Li Mingma , Yu Jing , Zhu Yuanyuan , Guo Hongxiong , Wang Zhiguo 

TITLE=Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China

JOURNAL=Frontiers in Public Health

VOLUME=11

YEAR=2023

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1272562

DOI=10.3389/fpubh.2023.1272562

ISSN=2296-2565

ABSTRACT=<sec id="sec1"><title>Background</title><p>This study is to evaluate the safety of two kinds of PCV13 carriers by monitoring the occurrence of adverse event following immunization (AEFI) after the launch of two kinds of PCV13 carriers in Jiangsu Province, China.</p></sec><sec id="sec2"><title>Methods</title><p>The AEFI Information System (CNAEFIS) of mainland China was used to monitor the incidence and classification of adverse reactions of the CRM197-carrier protein PCV13 and TT-carrier protein PCV13 vaccines.</p></sec><sec id="sec3"><title>Results</title><p>There was no statistical difference between the cumulative reported incidence of AEFI between the two vaccines from 2020 to 2022 (<italic>χ</italic><sup>2</sup> = 1.991, <italic>p</italic> &lt; 0.158). 96.62% of the AEFIs were classified as common reactions; rare reactions and coincidental events only accounted for 2.99 and 0.39% of all the AEFI cases, respectively. Redness (2.6 cm–5 cm) is the commonest symptom at the injection site for both vaccines. More than 97% of AEFIs occurred between 30 min and 3 days after administration for both types of PCV13.</p></sec><sec id="sec4"><title>Conclusion</title><p>Both vaccines perform well in terms of safety. We did not identify any new/unexpected safety concern from the NAEFISS during a 4 years timespan.</p></sec>